Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Presenting Author: Yvan Chanthery, Ph.D.
Date & Time: June 14, 2024 at 18:00 CEST

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/

The Adicet Bio Stock at the time of publication of the news with a fall of -2,28 % to 1,330USD on Tradegate stock exchange (13. Mai 2024, 22:26 Uhr).